World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
94
Citations
36825
World Ranking
10396
National Ranking
5352

Overview

Leo I. Gordon is affiliated with Northwestern University in the United States and has produced extensive research primarily within the field of medicine. Their work focuses on oncology, pathology and forensic medicine, genetics, immunology, and molecular biology. Their research contributions span more than 300 publications, with a significant emphasis on lymphoma diagnosis and treatment, CAR-T cell therapy research, and chronic lymphocytic leukemia research.

The main topics addressed in their research include:

  • Lymphoma Diagnosis and Treatment
  • CAR-T cell therapy research
  • Chronic Lymphocytic Leukemia Research
  • Immunotherapy and Immune Responses
  • CNS Lymphoma Diagnosis and Treatment
  • Biosimilars and Bioanalytical Methods
  • Lung Cancer Treatments and Mutations

Leo I. Gordon frequently publishes alongside the following co-authors:

  • Reem Karmali
  • Jane N. Winter
  • Shuo Ma
  • Adam Yuh Lin
  • Jonathan Moreira

Their preferred publication venues include:

  • Blood
  • Journal of Clinical Oncology
  • Blood Advances
  • Transplantation and Cellular Therapy
  • Journal of the National Comprehensive Cancer Network

Selected recent papers authored by Leo I. Gordon include:

  • Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study, 2020, The Lancet
  • Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma, 2021, New England Journal of Medicine
  • Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study, 2022, The Lancet Oncology
  • NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021, 2021, Journal of the National Comprehensive Cancer Network
  • Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology, 2020, Journal of the National Comprehensive Cancer Network

The scope and frequency of their publications demonstrate a sustained contribution to the advancement of therapeutic approaches and clinical guidelines in hematologic malignancies. The research includes clinical trials, guideline updates, and translational studies related to CAR-T cell therapies and lymphoma.

Best Publications

  • Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

    Thomas E. Witzig;Leo I. Gordon;Fernando Cabanillas;Myron S. Czuczman

  • Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.

    Jeremy S Abramson;M Lia Palomba;Leo I Gordon;Matthew A Lunning

  • Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy

    Myron S. Czuczman;A. J. Grillo-López;C. A. White;M. Saleh

  • Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.

    Kenneth R. Carson;Andrew M. Evens;Elizabeth A. Richey;Thomas M. Habermann

  • Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.

    Anupama Reddy;Jenny Zhang;Nicholas S. Davis;Andrea B. Moffitt

  • Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis

    Sigmund A. Weitzman;Leo I. Gordon

  • An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

    Zheng Zhou;Laurie H. Sehn;Alfred W. Rademaker;Leo I. Gordon

  • Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma

    Thomas E. Witzig;Ian W. Flinn;Leo I. Gordon;Christos Emmanouilides

  • Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+ B-Cell Non-Hodgkin's Lymphoma

    Thomas E. Witzig;Christine A. White;Gregory A. Wiseman;Leo I. Gordon

  • Genetic heterogeneity of diffuse large B-cell lymphoma

    Jenny Zhang;Vladimir Grubor;Cassandra L. Love;Anjishnu Banerjee

  • The genetic landscape of mutations in Burkitt lymphoma

    Cassandra Love;Zhen Sun;Dereje Jima;Guojie Li

  • Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial

    Philippe Armand;Arnon Nagler;Edie A. Weller;Steven M. Devine

  • Non-Hodgkin's Lymphomas

    Andrew D. Zelenetz;Ranjana H. Advani;John C. Byrd;Myron S. Czuczman

  • Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.

    Bruce D. Cheson;Stephen Ansell;Larry Schwartz;Leo I. Gordon

  • Comparison of a Second-Generation Combination Chemotherapeutic Regimen (m-BACOD) with a Standard Regimen (CHOP) for Advanced Diffuse Non-Hodgkin's Lymphoma

    Leo I. Gordon;David Harrington;Janet Andersen;Joseph Colgan

  • NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.

    Zelenetz Ad;Abramson Js;Advani Rh;Andreadis Cb

  • Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study

    Howard Hochster;Edie Weller;Randy D. Gascoyne;Thomas M. Habermann

  • Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial

    Gregory A. Wiseman;Leo I Gordon;Pratik S. Multani;Thomas E. Witzig

  • EFFICACY AND SAFETY OF

    Mary Beth Riley;Leo I. Gordon

  • NCCN guidelines ® insights hodgkin lymphoma, version 1.2018 featured updates to the NCCN guidelines

    Richard T. Hoppe;Ranjana H. Advani;Weiyun Z. Ai;Richard F. Ambinder

Frequent Co-Authors

Ranjana H. Advani
Ranjana H. Advani Stanford University
Nancy L. Bartlett
Nancy L. Bartlett Washington University in St. Louis
Andrew D. Zelenetz
Andrew D. Zelenetz Memorial Sloan Kettering Cancer Center
Myron S. Czuczman
Myron S. Czuczman Citius Pharmaceuticals, Inc.
Jonathan W. Friedberg
Jonathan W. Friedberg University of Rochester
Randy D. Gascoyne
Randy D. Gascoyne BC Cancer Agency
Alfred W. Rademaker
Alfred W. Rademaker Northwestern University
Richard T. Hoppe
Richard T. Hoppe Stanford University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine goes beyond traditional medical degrees. Numerous online degrees in nursing and healthcare offer flexible, affordable pathways for students and professionals seeking to advance or pivot their careers.

Many choose to begin their journey with adn nursing programs, which provide a foundational entry into nursing and can be a stepping stone to more advanced roles. For those already working as registered nurses, enrolling in one of the most affordable accredited online rn to bsn programs allows them to gain further qualifications and unlock new career opportunities.

Individuals from non-nursing backgrounds who wish to enter the nursing field can benefit from online msn programs for non nurses, which offer an accelerated path to advanced practice roles. For those aiming for the highest academic and professional levels, the cheapest phd nursing programs make earning a doctoral degree more accessible without compromising on quality.

These diverse online programs can help you tailor your educational path to your career goals in medicine and healthcare.

Best Scientists Citing Leo I. Gordon

Trending Scientists

Recently Published Articles